Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:6212 |
| Name | ovarian endometrial cancer |
| Definition | An ovary epithelial cancer that has_material_basis_in the endometrium and is located_in the ovary. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:4116 |
| Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer ovarian endometrial cancer |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01844986 | Phase III | Olaparib | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1) | Active, not recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | CAN | BRA | AUS | 4 |
| NCT02068794 | Phase Ib/II | MV-NIS | MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02345265 | Phase II | Cediranib + Olaparib | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
| NCT02983799 | Phase II | Olaparib | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | Completed | USA | CAN | 0 |
| NCT03395080 | Phase II | DKN-01 DKN-01 + Paclitaxel | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) (P204) | Completed | USA | 0 |
| NCT03462212 | Phase Ib/II | Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) | Unknown status | ITA | 0 |
| NCT03602859 | Phase III | Dostarlimab-gxly + Niraparib Niraparib | A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) | Active, not recruiting | USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | 2 |
| NCT04261465 | Phase II | Carboplatin + Olaparib + Paclitaxel | NUVOLA TRIAL Open-label Multicentre Study (NUVOLA) | Unknown status | ITA | 0 |
| NCT04460807 | Phase III | Exemestane | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT) | Terminated | ITA | 0 |
| NCT04669002 | Phase II | NLG207 + Olaparib | EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | Completed | USA | HUN | GBR | 0 |
| NCT04729387 | Phase III | Pegylated liposomal doxorubicin Paclitaxel Alpelisib + Olaparib | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | Active, not recruiting | USA | TUR | SVK | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT04931342 | Phase II | Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Active, not recruiting | USA | TUR | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 1 |
| NCT05065021 | Phase II | Bevacizumab + Dostarlimab-gxly + Niraparib Bevacizumab + Niraparib Bevacizumab + Dostarlimab-gxly + Paclitaxel | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | Recruiting | CAN | 0 |
| NCT05295589 | Phase II | Topotecan Pegylated liposomal doxorubicin Copanlisib + Olaparib Paclitaxel | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | Withdrawn | USA | 0 |
| NCT06787612 | Phase II | Bevacizumab + Sarilumab + Ubamatamab Sarilumab + Ubamatamab Pegylated liposomal doxorubicin + Sarilumab + Ubamatamab Cemiplimab + Fianlimab + Sarilumab + Ubamatamab | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Recruiting | USA | TUR | 2 |
| NCT06915025 | Phase III | Carboplatin + GEN-1 + Niraparib + Paclitaxel Carboplatin + GEN-1 + Olaparib + Paclitaxel Carboplatin + Olaparib + Paclitaxel Carboplatin + Niraparib + Paclitaxel | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer (OVATION-3) | Recruiting | USA | 0 |
| NCT07211659 | Phase II | THEO-260 | Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients (OCTOPOD-IP) | Not yet recruiting | USA | 0 |